Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Binimetinib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre

Drug Profile

Binimetinib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre

Alternative Names: ARRY-162; ARRY-438162; Balimek; MEK-162; MEKTOVI; ONO-7703

Latest Information Update: 07 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Childrens Hospital Los Angeles; Dana-Farber Cancer Institute; German Cancer Research Center; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; Merck KGaA; National Cancer Institute (USA); Novartis; Ono Pharmaceutical; Pfizer; Pierre Fabre; Plexxikon; Seoul National University Hospital; Swiss Group for Clinical Cancer Research; University Health Network; University of Heidelberg; University of Pittsburgh
  • Class Amides; Anti-inflammatories; Antineoplastics; Benzimidazoles; Fluorine compounds; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Haematological malignancies; Multiple myeloma; Neurofibromatoses; Non-small cell lung cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia; Biliary cancer; Breast cancer; Cancer; Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Pancreatic cancer
  • Discontinued Rheumatoid arthritis; Uveal melanoma

Most Recent Events

  • 05 Feb 2019 Launched for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in United Kingdom, Netherlands, Austria, Germany (PO)
  • 04 Feb 2019 Array biopharma completes enrollment in a phase-III BEACON CRC trial in Colorectal cancer (Second-line therapy or greater, Metastatic disease, Combination therapy) in Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, England, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Russia, Scotland, South Korea, Spain, Taiwan, Turkey, Ukraine, United Kingdom, USA (PO) (NCT02928224)
  • 17 Jan 2019 Array BioPharma, Merck KGaA and Pierre Fabre Medicament initiates the phase II ANCHOR-CRC trial for Colorectal cancer in USA and Spain (First-line therapy, Metastatic disease, Combination therapy) (NCT03693170)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top